Management of Pulmonary Arterial Hypertension with Sitaxentan Sodium

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease with a poor prognosis if left untreated. Pathophysiological alterations in this disease lead to vasoconstriction, endothelial and smooth muscle cell proliferation, and in situ thrombosis. Endothelin-1 (one of the most potent...

Full description

Saved in:
Bibliographic Details
Published inClinical Medicine Insights: Therapeutics Vol. 2011; no. 3; pp. 31 - 38
Main Authors Pulido, Tomas, Murillo, Carla, Ramírez-Neria, Paulina, Hurtado, Viridiana, de la Garza, Paola, Astorga, Sandra, Miranda, María Teresa, Sandoval, Julio
Format Journal Article Book Review
LanguageEnglish
Published London, England Libertas Academica 01.01.2011
SAGE Publishing
SAGE Publications
Sage Publications Ltd
Subjects
endothelin receptor antagonists
pulmonary arterial hypertension
sitaxentan
Online AccessGet full text

Cover

More Information
Summary:Pulmonary arterial hypertension (PAH) is a chronic and progressive disease with a poor prognosis if left untreated. Pathophysiological alterations in this disease lead to vasoconstriction, endothelial and smooth muscle cell proliferation, and in situ thrombosis. Endothelin-1 (one of the most potent vasconstrictors known), has been shown to be increased in PAH, contributing, in part at least, to these abnormalities. Endothelin acts through the binding of two receptors, ETA and ETB. Sitaxentan is a selective ETA endothelin receptor antagonist that has been demonstrated, in several clinical trials, to improve exercise capacity, functional class and hemodynamics. Sitaxentan has a good safety profile, is well tolerated and has a low incidence of liver toxicity.
ISSN:1179-559X
1179-559X
DOI:10.4137/CMT.S5954